US FDA clears four new generics by Indian cos (Hindustan Times)
Indian drugmakers, two of which have Mumbai connections, got approvals to market four generic drugs with a cumulative market size of three and a-quarter billion dollars (Rs 15,000 crore).

MedaSorb Announces IDE Filing With the FDA; Following Approval MedaSorb Will Begin Multi-Site Pilot Study (RedNova)
MONMOUTH JUNCTION, N.J., Jan. 4, 2007 (PRIME NEWSWIRE) -- MedaSorb Technologies Corporation (OTCBB:MSBT) today announced that is has submitted an Investigational Device Exemption (IDE) Supplement to the FDA for its CytoSorb(tm) hemoperfusion blood filtration device.

DURECT Starts Phase II Dosing for TRANSDUR(TM)-Bupivacaine (DUR-843) (FinanzNachrichten)
CUPERTINO, Calif., Jan. 3 /PRNewswire-FirstCall/ -- DURECT Corporation ( Nachrichten ) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal pain patch for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN). DURECT's Phase I trial for ...